STAT-3 activation is necessary for ischemic preconditioning in hypertrophied myocardium

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 2, 2006, Pages

  Butler, Karyn L ^a   Huffman, Lynn C ^a   Koch, Sheryl E ^a   Hahn, Harvey S ^b   Gwathmey, Judith K ^c,d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Gwathmey Inc   (United States)

Author keywords

Cardiac preconditioning; Ischemia reperfusion; Janus activated kinase; Myocardial hypertrophy; Signal transducer and activator of transcription

Indexed keywords

JANUS KINASE 2; JANUS KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT1 PROTEIN; STAT3 PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE VOLUME; HEART VENTRICLE WALL; ISCHEMIC HEART DISEASE; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; BIOTRANSFORMATION; BLOTTING, WESTERN; CARDIOMEGALY; ECHOCARDIOGRAPHY; HEMODYNAMIC PROCESSES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MUSCLE CONTRACTION; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; STAT3 TRANSCRIPTION FACTOR;

EID: 33746824143     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01334.2005     Document Type: Article

References (29)

1. Bolli R. The late phase of preconditioning. Circ Res 87: 972-983, 2000.
2. Bolli R, Becker L, Gross G, Mentzer R, Balshaw D, and Lathrop DA. Myocardial protection at a crossroads. The need for translation into clinical therapy. Circ Res 95: 125-134, 2004.
3. Bolli R, Dawn B, and Xuan Y. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. TCM 13: 72-79, 2003.
4. Booz GW, Day JN, and Baker KM. Interplay between the cardiac renin-angiotensin system and JAK/STAT signaling: role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol 34: 1443-1453, 2002.
5. 1 receptor blockade enhances ischemic preconditioning in hypertrophied rat myocardium. Am J Physiol Heart Circ Physiol 277: H2482-H2487, 1999.
6. Cohen MV, Baines CP, and Downey JM. Ischemic preconditioning: from adenosine receptor to KATP channel. Annu Rev Physiol 62: 79-109, 2000.
7. Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, Siddiqui MQ, and Das DK. Role of STAT-3 in ischemic preconditioning. J Mol Cell Cardiol 33: 1929-1936, 2001.
8. Ivashkiv LB. Cytokines and STATs: how can signals achieve specificity? Immunity 3: 1-4, 1995.
9. Ivashkiv LB and Hu X. Signaling by STATs. Arthritis Res Ther 6: 159-168, 2004.
10. Jacoby JJ, Kalinowski A, Liu M, Zhang SS, Gao Q, Chai G, Ji L, Iwamoto Y, Li E, Schneider M, Russell KS, and Fu X. Cardiomyocyte-restricted knockout of STAT-3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 100: 12929-12934, 2003.
11. Kisseleva T, Bhattacharya S, Braunstein J, and Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1-24, 2002.
12. Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, Yamada S, Okabe M, Tadamitsu K, and Yamauchi-Takihara K. Signal transducer and activator of transcription-3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 97: 315-319, 2000.
13. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, and Kishimoto T. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98: 346-352, 1998.
14. Miyamoto T, Takeishi Y, Takahashi H, Shishido T, Arimoto T, Tomoike H, and Kubota I. Activation of distinct signal transduction pathways in hypertrophied hearts by pressure and volume overload. Basic Res Cardiol 99: 328-337, 2004.
15. Morisco C, Sadoshima J, Trimarco B, Arora R, Vatner DE, and Vatner SF. Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. Am J Physiol Heart Circ Physiol 284: H1043-H1047, 2003.
16. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
17. Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M, Oshima Y, Nakaoka Y, Hirota H, Kishimoto T, and Yamauchi-Takihara K. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the up-regulation of manganese superoxide dismutase. Circulation 104: 979-981, 2001.
18. Negoro S, Kunisada K, Tone E, Funamoto M, Oh H, Kishimoto T, and Yamauchi-Takihara K. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 47: 797-805, 2000.
19. Omura T, Yoshiyama M, Ishikura F, Kobayashi H, Takeuchi K, Beppu S, and Yoshikawa J. Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. J Mol Cell Cardiol 33: 307-316, 2001.
20. Oshima U, Fujio Y, Nakanishi T, Itoh N, Yamamoto Y, Negoro S, Tanaka K, Kishimoto T, Kawase I, and Azuma J. STAT-3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 65: 428-435, 2005.
21. Pan J, Fukuda K, Saito M, Matsuzaki J, Kodama H, Sano M, Takahashi T, Kato T, and Ogawa S. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 84: 1127-1136, 1999.
22. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, and Drexler H. Alterations in Janus Kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 107: 798-802, 2003.
23. Przyklenk K, Darling CE, Dickson EW, and Whittaker P. Cardioprotection 'outside the box' - the evolving paradigm of remote preconditioning. Basic Res Cardiol 98: 149-157, 2003.
24. Sahn DJ, DeMaria A, Kisslo J, and Weyman A. Recommendations regarding quantization in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
25. Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR, and Sack MN. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 63: 611-616, 2004.
26. Stephanou A, Brar BK, Scarabelli TM, Jonassen AK, Yellon DM, Marber MS, Knight RA, and Latchman DS. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem 275: 10002-10008, 2000.
27. Uozumi H, Hiroi Y, Zou Y, Takimoto E, Toko H, Niu P, Shimoyama M, Yazaki Y, Nagai R, and Komuro I. Gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem 276: 23115-23119, 2001.
28. Xuan YT, Guo Y, Han H, Zhu Y, and Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 98: 9050-9055, 2001.
29. Zhong Z, Wen Z, and Darnell JE. STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98, 1994.